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Cystic fibrosis (CF) is the most common auto-
somal recessive disorder in Caucasians. Since the 
first description of CF as a separate disease entity 
by the pathologist Dorothy Andersen in 1938, the 
demographic and clinical characteristics of the 
patient population have changed beyond recog-
nition [1]. At the time of the first description of 
CF, the diagnosis was devastating, with more than 
70% of children dying during the first year of life, 
usually from meconium ileus, severe malnutrition 
or respiratory failure. 
Considerable changes in both CF course 
and survival of patients have been seen. It is no 
longer a disease exclusively of childhood. The 
proportion of adult patients in many countries 
is very high. The number of adults with CF now 
outnumber the children with CF in developed 
countries [2]. In registry of United Kingdom for 
example, 57.6% of all CF patients are classified 
as adults [3]. 
In Poland, this exceeded one-third of patients 
in 2012. This needs good translation from chil-
dren to adult centres in order to continue good 
standards of care. The best locations for these 
centres may be academic respiratory departments.
It is very interesting to present in this issue of 
“Advances in Respiratory Medicine”, two articles 
related to CF problems. In an article by Chatterjee 
et al. [4], the example of national trends in the 
CF status of patients and care was presented. 
This information should be helpful in developing 
practice guidelines in order to improve quality of 
inpatient care, decreasing iatrogenic complica-
tions, providing valuable prognostic information, 
and identifying new challenges in the manage-
ment of the increasing population of individuals 
with CF. A second article by Hassanzad et al. [5] 
from Iran gives us an opportunity to recognize 
another example of a CF national group. Clinical 
characteristics may be an important example. The 
interesting data about CF population presented in 
this paper should be a challenge for respiratory 
physicians who should develop their responsi-
bility for CF patients. 
In Poland, cystic fibrosis occurs in approx-
imately one in 4,400 newborns. It is estimated 
that the annual incidence rate in Poland amounts 
each year to approximately 70−80 new cases [6]. 
According to the Polish Cystic Fibrosis Registry 
maintained by the Polish Cystic Fibrosis Society 
(now suspended because of transitional period 
in legislation), in 2012 there were about 1,500 
patients with this disease in our country while 
the percentage of adult patients, who had com-
pleted 18 years of age, was 33%. The data confirm 
a significant increase in survival time of patients 
in recent decades in our country. It has become 
an important challenge to take care of a group of 
more than 500 adults with cystic fibrosis. Res-
piratory physicians dealing with the problems 
of adults from relatively recently are discovering 
the necessity of providing care for these patients. 
Even though CF is a multiorgan disease, pro-
gressive lung destruction is the most common 
cause of morbidity and mortality. Especially the 
problems associated with the respiratory system 
seem to be the most frequently manifested with 
such problems also comprising the majority of 
the causes of failure and death.
The reason for a steady improvement in me-
dian survival with an increasing adult population 
is a result of multiple factors, classified into ge-
netic and non-genetic groups. Non-genetic factors 
include environmental (sex, tobacco smoke expo-
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sure and climate), health-care related (access to 
special CF centres, infection control quality and 
adherence) and socioeconomic factors. 
Poor nutrition, colonization of respiratory 
tract pathogens such as Pseudomonas aeruginosa 
or Burkholderia cenocepacia, untreated CF-related 
diabetes, and the female sex are well established 
factors associated with worse outcomes in CF. 
The crucial key points over the years have in-
cluded the implementation of rational antibiotic 
regimens, pancreatic enzymes, optimization of 
nutrition, effective airway clearance with the 
use of physiotherapy techniques, drugs which 
increase sputum clearance (e.g. dornase alfa), 
lung transplantation, and the introduction of 
mutation-specific protein-modulating drugs. The 
emergence of personalized pharmacological CFTR 
potentiators and correctors, based on a CFTR gen-
otype, offers exciting new possibilities for some 
patients with CF. 
These, combined with better CF care deliv-
ered by a specialist multidisciplinary team mod-
erated by respiratory physicians, have been the 
most important factors leading to patients living 
longer and with a better quality of life. 
Improvements in the diagnosis of CF have 
also contributed to an increase in survival. The 
diagnostic possibilities in Poland, related to a new-
born screening which is obligatory and well or-
ganized, could be an example for other countries. 
Respiratory manifestations of CF are always 
the most important challenges of current care. 
Significant improvement in the management of 
the respiratory complications of CF have meant 
that extrapulmonary complications are becoming 
more prevalent. Extrapulmonary manifestations 
of CF are an increasing problem as the morbid-
ities of aging are added to the “usual” CF com-
plications. CF-related diabetes occurs in about 
45% of adults over 40 years of age and is an 
independent predictor of mortality. CF-associated 
liver disease is also a difficult problem. Chronic 
kidney disease increases with age while the risk 
doubles with every additional ten years of age. 
The prevalence of osteoporosis and the risk of ma-
lignancy increases with age. A higher incidence 
of osteoporotic fractures in CF patients implicates 
screening and early treatment of osteoporosis. 
Current data demonstrate a significant increase 
in gastrointestinal cancer risk in CF. 
There is a long list of important and very 
different challenges which are important for 
patients, their families and CF medical teams. 
These range from respiratory failure and lung 
transplantation to various social issues. 
Disease complexity is changing in CF as 
the life expectancy of the patient population 
increases. The unique subset of microbes that 
commonly infect the lower respiratory tract 
of individuals with CF has evolved over time. 
There is also a growing recognition of the 
clinical importance of non-tuberculous myco-
bacteria in CF. Fungal infections should also be 
considered: attention to fungal infections and 
the evidence of clinical impact has increased. 
Fungal colonization and infection in this group 
of patients is frequent and is dominated by As-
pergillus fumigatus. 
It has been confirmed that the health care of 
CF patients provided in specialist centres is more 
effective and results in better clinical outcomes. 
In the indications concerning the care of patients 
with CF it is suggested that centres include the 
care of at least 100 adults [7, 8].
International and national standards are 
a good aid in the work of adult specialists. In 
recent years, standards have been published de-
scribing the principles of care [9], the structure 
of the organisation of CF centres [10] and prin-
ciples of infection control [11]. Polish guidelines 
have also been presented which are becoming 
an important element of education of medical 
staff [12]. 
The transition of young adults with CF from 
paediatric to adult medical care is an important 
priority. The transition to adulthood, a develop-
mental process of skill-building in self-manage-
ment supported by the health system, is impor-
tant for the successful transfer to adult CF care. 
Interesting transition programs from childhood to 
adult CF care have also been presented in recent 
years [13, 14]. There is also a place for such pro-
grams in the Polish context. The transition and 
transfer process needs to be integrated into the 
patient’s and family environment CF is poised 
to become a model for the successful transition 
of care for all adolescents and young adults with 
chronic health conditions and special health 
care needs.
CF treatment and care are changing rapidly 
and have resulted in improved patient survival. 
The burden of care and disease complexity are 
increasing. It implicates to take the best possible 
care concerning medical and non-medical prob-
lems and which should be carried by multi-spe-
cialist team of medical staff. The standards of 
paediatric CF care are well established in Poland. 
The necessity of the formation of specialized 
adult CF centres will become the most important 
challenge of future decades. 
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